Cargando…

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease

Results from recent randomized controlled trials on inhibitors of the sodium-glucose cotransporter 2 (SGLT2) have determined a paradigm shift in the treatment of patients with type 2 diabetes mellitus. These agents have been shown not only to ameliorate metabolic control, but also to independently p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Podestà, Manuel Alfredo, Sabiu, Gianmarco, Galassi, Andrea, Ciceri, Paola, Cozzolino, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953060/ https://www.ncbi.nlm.nih.gov/pubmed/36830815 http://dx.doi.org/10.3390/biomedicines11020279

Ejemplares similares

Calciphylaxis after kidney transplantation: a rare but life-threatening disorder
por: Podestà, Manuel Alfredo, et al.
Publicado: (2021)

Vitamin K in Chronic Kidney Disease
por: Cozzolino, Mario, et al.
Publicado: (2019)

Current Therapy in CKD Patients Can Affect Vitamin K Status
por: Cozzolino, Mario, et al.
Publicado: (2020)

Early aging and premature vascular aging in chronic kidney disease
por: Tanriover, Cem, et al.
Publicado: (2023)

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
por: De Nicola, Luca, et al.
Publicado: (2022)

Do we need new phosphate binders in dialysis?
por: Cozzolino, Mario, et al.
Publicado: (2020)

Phosphate binders in dialysis: better satisfied than sorry
por: Cozzolino, Mario, et al.
Publicado: (2021)

Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease
por: Ciceri, Paola, et al.
Publicado: (2022)

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
por: Wheeler, David C., et al.
Publicado: (2020)

Immune responses to SARS-CoV-2 in dialysis and kidney transplantation
por: Cantarelli, Chiara, et al.
Publicado: (2022)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

Cardiovascular disease in dialysis patients
por: Cozzolino, Mario, et al.
Publicado: (2018)

Dabigatran overload in acute kidney injury: haemodialysis or idarucizumab? A case report and proposal for a decisional algorithm
por: Galassi, Andrea, et al.
Publicado: (2020)

Magnesium: a renewed player of vascular ageing in diabetic CKD patients?
por: Galassi, Andrea, et al.
Publicado: (2014)

SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
por: Mark, Patrick B, et al.
Publicado: (2023)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

Effects of a medium cut-off (Theranova(®)) dialyser on haemodialysis patients: a prospective, cross-over study
por: Cozzolino, Mario, et al.
Publicado: (2019)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
por: Pham, Phuong-Thu T., et al.
Publicado: (2022)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2017)

A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
por: Liu, Allen Yan Lun, et al.
Publicado: (2022)

Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors
por: Kovesdy, Csaba, et al.
Publicado: (2022)

1,25-dihydroxyvitamin D as Predictor of Renal Worsening Function in Chronic Kidney Disease. Results From the PASCaL-1,25D Study
por: Galassi, Andrea, et al.
Publicado: (2022)

Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19
por: Galassi, Andrea, et al.
Publicado: (2022)

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2018)

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
por: Jeong, Su Jin, et al.
Publicado: (2021)

SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
por: Klen, Jasna, et al.
Publicado: (2023)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy
por: Matthews, Jennifer Rose, et al.
Publicado: (2022)

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
por: Vasquez-Rios, George, et al.
Publicado: (2020)

Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia
por: Durcan, Emre, et al.
Publicado: (2022)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
por: Skrabic, Roko, et al.
Publicado: (2022)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
por: Lu, Yong-Ping, et al.
Publicado: (2022)

The Key Role of Phosphate on Vascular Calcification
por: Cozzolino, Mario, et al.
Publicado: (2019)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2vhtm8uspuoa66p01hbms35gdp